Haisco Pharmaceutical Group (002653) Stock Overview
Researches, develops, manufactures, and sells pharmaceutical products primarily in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
002653 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Haisco Pharmaceutical Group Co., Ltd. Competitors
Shenzhen Salubris Pharmaceuticals
China Resources Sanjiu Medical & Pharmaceutical
Shanghai Fosun Pharmaceutical (Group)
Sichuan Kelun Pharmaceutical
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥58.48 |
| 52 Week High | CN¥62.65 |
| 52 Week Low | CN¥40.70 |
| Beta | -0.19 |
| 1 Month Change | 26.20% |
| 3 Month Change | 8.82% |
| 1 Year Change | 29.38% |
| 3 Year Change | 109.68% |
| 5 Year Change | 129.69% |
| Change since IPO | 730.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002653 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 4.8% | -1.5% | 5.2% |
| 1Y | 29.4% | 11.1% | 31.3% |
Return vs Industry: 002653 exceeded the CN Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: 002653 underperformed the CN Market which returned 31.3% over the past year.
Price Volatility
| 002653 volatility | |
|---|---|
| 002653 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 002653 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002653's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 5,597 | Xiu Lian Fan | www.haisco.com |
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. The company offers pharmaceutical products in the areas of anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory, narcotic analgesics, endocrine system, enteral parenteral, nutrition, neuropsychiatric, cardiovascular, digestive liver, and other diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 002653 fundamental statistics | |
|---|---|
| Market cap | CN¥67.25b |
| Earnings (TTM) | CN¥259.58m |
| Revenue (TTM) | CN¥4.39b |
Is 002653 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002653 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.39b |
| Cost of Revenue | CN¥1.27b |
| Gross Profit | CN¥3.12b |
| Other Expenses | CN¥2.86b |
| Earnings | CN¥259.58m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 27, 2026
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 71.14% |
| Net Profit Margin | 5.92% |
| Debt/Equity Ratio | 45.8% |
How did 002653 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 09:12 |
| End of Day Share Price | 2026/04/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haisco Pharmaceutical Group Co., Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chao Li | Citic Securities Co., Ltd. |
| Qianli Ma | Guosen Securities Co., Ltd. |
| Jiabo Zhang | Guosen Securities Co., Ltd. |